CISH inhibitors or CISH degraders e.g. homo-PROTACs could offer a new avenue in the development of cancer therapies; in the latter case essentially offering a chemically-induced pharmacological equivalent to a CISH knock-down, which could serve as an orthogonal approach to the work of ONK therapeutics discussed above. The gene discussed is CISH; the disease is cancer.